Vinodh Kakkassery1, Steffen Emmert2, Irenäus A Adamietz3, György Kovács4,5, Anselm M Jünemann6, Caroline Otte7, Michael Zimbelmann7, Anton Brosig7, Salvatore Grisanti7, Ludwig M Heindl8,9. 1. Klinik für Augenheilkunde, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland. vinodh.kakkassery@gmail.com. 2. Klinik und Poliklinik für Dermatologie, Universitätsmedizin Rostock, Rostock, Deutschland. 3. Radioonkologie, Ruhr-Universität Bochum, Bochum, Deutschland. 4. Gemelli INTERACTS - Università Cattolica del Sacro Cuore, Rom, Italien. 5. Bereich Interdisziplinäre Brachytherapie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland. 6. Klinik und Poliklinik für Augenheilkunde, Universitätsmedizin Rostock, Rostock, Deutschland. 7. Klinik für Augenheilkunde, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland. 8. Zentrum für Augenheilkunde, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Köln, Deutschland. 9. Centrum für Integrierte Onkologie (CIO) Aachen-Bonn-Köln-Düsseldorf, Köln, Deutschland.
Abstract
BACKGROUND: Latest developments as well as established procedures offer alternative treatment approaches to basal cell carcinoma (BCC) when micrographically controlled surgical removal is not a valid option. OBJECTIVE: Alternative treatment options for periorbital BCC are presented. METHODS: A literature search was carried out and a structured display and analysis of the results are given. RESULTS: Micrographically controlled surgical removal represents the gold standard in treatment of BCC. When for various reasons surgical removal is not a valid option, other procedures are required. The alternative treatment options can be divided into three main groups: treatment options for locally advanced or metastasized BCC, topical approaches for small and superficial BCC and prophylactic measures. While radiotherapy and systemic therapy are suitable for locally advanced BCC and are discussed in a tumor board, small and superficial BCC can be treated by topical medication. In cases of a previous BCC history, a prophylactic treatment can be considered. Combinations of systemic treatment and also neoadjuvant or adjuvant approaches before and after surgery are promising options for a successful outcome, which can further improve the standard treatment for locally advanced BCC. CONCLUSION: Alternative treatment options for periocular BCC are available; however, the use is only indicated when microscopically controlled excision with subsequent oculoplastic reconstruction is not possible. According to the national guidelines a prior presentation to a suitable tumor board is practically compulsory.
BACKGROUND: Latest developments as well as established procedures offer alternative treatment approaches to basal cell carcinoma (BCC) when micrographically controlled surgical removal is not a valid option. OBJECTIVE: Alternative treatment options for periorbital BCC are presented. METHODS: A literature search was carried out and a structured display and analysis of the results are given. RESULTS: Micrographically controlled surgical removal represents the gold standard in treatment of BCC. When for various reasons surgical removal is not a valid option, other procedures are required. The alternative treatment options can be divided into three main groups: treatment options for locally advanced or metastasized BCC, topical approaches for small and superficial BCC and prophylactic measures. While radiotherapy and systemic therapy are suitable for locally advanced BCC and are discussed in a tumor board, small and superficial BCC can be treated by topical medication. In cases of a previous BCC history, a prophylactic treatment can be considered. Combinations of systemic treatment and also neoadjuvant or adjuvant approaches before and after surgery are promising options for a successful outcome, which can further improve the standard treatment for locally advanced BCC. CONCLUSION: Alternative treatment options for periocular BCC are available; however, the use is only indicated when microscopically controlled excision with subsequent oculoplastic reconstruction is not possible. According to the national guidelines a prior presentation to a suitable tumor board is practically compulsory.
Entities:
Keywords:
Hedgehog protein inhibitors; Irradiation; Prophylaxis; Topical treatment; Tumor board
Authors: Maya Eiger-Moscovich; Ehud Reich; Gil Tauber; Ori Berliner; Ayelet Priel; Guy Ben Simon; Amir Abd Elkader; Iftach Yassur Journal: Am J Ophthalmol Date: 2019-05-09 Impact factor: 5.258
Authors: Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin Journal: Lancet Oncol Date: 2015-03-18 Impact factor: 41.316
Authors: Hywel C Williams; Fiona Bath-Hextall; Mara Ozolins; Sarah J Armstrong; Graham B Colver; William Perkins; Paul S J Miller Journal: J Invest Dermatol Date: 2016-12-05 Impact factor: 8.551
Authors: Maurizio Valeriani; Luca Nicosia; Linda Agolli; Chiara Reverberi; Emanuela Galvagno; Vitaliana DE Sanctis; Giuseppe Minniti; Marta Carlesimo; Mattia F Osti Journal: Anticancer Res Date: 2017-02 Impact factor: 2.480
Authors: Rosa Ballester-Sánchez; Olga Pons-Llanas; Cristian Candela-Juan; Francisco Javier Celada-Alvarez; Blanca de Unamuno-Bustos; Margarita Llavador-Ros; Antonio Ballesta-Cuñat; Christopher A Barker; Alejandro Tormo-Mico; Rafael Botella-Estrada; Jose Perez-Calatayud Journal: J Contemp Brachytherapy Date: 2015-06-09